World journal of radiology · 2026
Portal vein embolization for arterio-portal shunt closure in hepatocellular carcinoma to facilitate selective internal radiation therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Xue, Zhao Jin-Yan, Xu Zhen-Yuan, Shen Shu-Qun, Xu Zhi-Jia, Yang Ye-Fa, Ge Nai-Jian, Wang Xiang-Dong
Аннотация
BACKGROUND: Selective internal radiation therapy (SIRT) has been widely used in the treatment of hepatocellular carcinoma (HCC). However, marked intrahepatic shunt (IHS) secondary to arterio-portal shunt (APS) often precludes safe SIRT administration.
AIM: To evaluate the efficacy and safety of portal vein embolization (PVE) in reducing IHS and enabling SIRT therapy in HCC patients with APS.
METHODS: This retrospective study enrolled seven HCC patients with APS confirmed by hepatic angiography during mapping. PVE was performed to close the APS outlet and single photon emission computed tomography/computed tomography was performed to determine the distribution of (99m) technetium-labeled macroaggregated albumin. These patients meeting the criteria for SIRT subsequently underwent Yttrium-90 (Y-90) resin microspheres administration. Changes in liver function and complications were monitored during the 6-month follow-up period.
RESULTS: Complete APS occlusion was achieved in six patients (n = 6, 6/7). The hepatopulmonary shunt rate was below 20% (4.65%-16.95%) in five of six patients with APS occluded, and Y-90-SIRT was subsequently administered in these patients. No severe procedural complications occurred.
CONCLUSION: PVE is a safe and effective strategy to reduce IHS in HCC patients with APS, thereby improving eligibility for SIRT.
AIM: To evaluate the efficacy and safety of portal vein embolization (PVE) in reducing IHS and enabling SIRT therapy in HCC patients with APS.
METHODS: This retrospective study enrolled seven HCC patients with APS confirmed by hepatic angiography during mapping. PVE was performed to close the APS outlet and single photon emission computed tomography/computed tomography was performed to determine the distribution of (99m) technetium-labeled macroaggregated albumin. These patients meeting the criteria for SIRT subsequently underwent Yttrium-90 (Y-90) resin microspheres administration. Changes in liver function and complications were monitored during the 6-month follow-up period.
RESULTS: Complete APS occlusion was achieved in six patients (n = 6, 6/7). The hepatopulmonary shunt rate was below 20% (4.65%-16.95%) in five of six patients with APS occluded, and Y-90-SIRT was subsequently administered in these patients. No severe procedural complications occurred.
CONCLUSION: PVE is a safe and effective strategy to reduce IHS in HCC patients with APS, thereby improving eligibility for SIRT.